 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...219220221222223224225226227228229...235236» |
- ||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial initiation date, Metastases: Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 23, 2014
P2, N=120, Not yet recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Initiation date: Sep 2013 --> Feb 2014
- methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change: CRUK-BRD/07/004: Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - Jan 23, 2014
P1/2, N=4, Completed, Sponsor: University College, London
Initiation date: Sep 2013 --> Feb 2014 N=20 --> 4
- | Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer (clinicaltrials.gov) - Jan 23, 2014
P2, N=30, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion: CRUK-BRD/07/004: Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - Jan 23, 2014
P1/2, N=4, Completed, Sponsor: University College, London
N=20 --> 4 Recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Biomarker, New P2 trial, Metastases: Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 22, 2014
P2, N=52, Recruiting, Sponsor: CR-CSSS Champlain-Charles-Le Moyne
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial initiation date, Combination therapy, Metastases: Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jan 21, 2014
P=N/A, N=30, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed Initiation date: Oct 2013 --> Jan 2014
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial initiation date: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Jan 21, 2014
P2, N=360, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Initiation date: Oct 2013 --> Jan 2014 Initiation date: Oct 2012 --> Jun 2013
- ||||| Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
New P2 trial: Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma (clinicaltrials.gov) - Jan 21, 2014
P2, N=100, Recruiting, Sponsor: University of California, San Diego
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Combination therapy, Metastases: Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jan 21, 2014
P=N/A, N=30, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Oct 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment open: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Jan 21, 2014
P2, N=360, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Inlyta (axitinib) / Pfizer
Enrollment closed, Metastases: A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jan 21, 2014
P2, N=69, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Erivedge (vismodegib) / Roche
Trial completion: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study (clinicaltrials.gov) - Jan 21, 2014
P2, N=19, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Mekinist (trametinib) / Novartis, BeiGene
New P2 trial, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 20, 2014
P2, N=89, Recruiting, Sponsor: National Cancer Institute (NCI)
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P1 trial, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 20, 2014
P1, N=34, Not yet recruiting, Sponsor: City of Hope Medical Center
- |||| Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Enrollment open: Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma (clinicaltrials.gov) - Jan 20, 2014
P2, N=100, Recruiting, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- bortezomib / Generic mfg.
Trial suspension, Combination therapy: AALL07P1: Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jan 19, 2014
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Suspended
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Jan 19, 2014
P2, N=66, Recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||| imgatuzumab (RO5083945) / Centessa
Trial completion, Combination therapy, Metastases: A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 19, 2014
P2, N=169, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Kinselby (resminostat) / 4SC, Yakult Honsha
Enrollment change, Combination therapy, Metastases: SHORE: 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (clinicaltrials.gov) - Jan 14, 2014
P1/2, N=17, Active, not recruiting, Sponsor: 4SC AG
Active, not recruiting --> Completed N=80 --> 17
- ||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer (clinicaltrials.gov) - Jan 14, 2014
P3, N=107, Completed, Sponsor: Sanofi
N=80 --> 17 Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Jan 13, 2014
P2, N=66, Recruiting, Sponsor: Case Comprehensive Cancer Center
- ||| duligotuzumab (MEHD7945A) / Roche
Enrollment closed, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jan 12, 2014
P2, N=135, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| onartuzumab (RG3638) / Roche
Enrollment closed, Combination therapy, Metastases: A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer (clinicaltrials.gov) - Jan 12, 2014
P2, N=123, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | veliparib (ABT-888) / AbbVie
New P1 trial, Combination therapy: A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Jan 9, 2014
P1, N=42, Enrolling by invitation, Sponsor: AbbVie
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Jan 6, 2014
P1, N=30, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Suspended --> Recruiting
- leucovorin calcium / Generic mfg., vinblastine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=376, Completed, Sponsor: Histiocyte Society
Suspended --> Recruiting Active, not recruiting --> Completed
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 5, 2014
P2, N=40, Recruiting, Sponsor: Yuhong Li
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 5, 2014
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Metastases: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 2, 2014
P1, N=83, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| aminopterin / Syntrix
Trial completion, Grant: Aminopterin in Treating Patients With Refractory Leukemia (clinicaltrials.gov) - Jan 1, 2014
P2, N=75, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, Metastases: Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer (clinicaltrials.gov) - Dec 29, 2013
P3, N=240, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, Metastases: Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC (clinicaltrials.gov) - Dec 29, 2013
P3, N=240, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- ||| napabucasin (BBI608) / Sumitomo Pharma
New P1 trial, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Dec 29, 2013
P1, N=144, Recruiting, Sponsor: Boston Biomedical, Inc
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma (clinicaltrials.gov) - Dec 26, 2013
P2, N=35, Recruiting, Sponsor: Yuhong Li
- methotrexate IV / Generic mfg.
New P2 trial, Adverse events: Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? (clinicaltrials.gov) - Dec 25, 2013
P2, N=38, Recruiting, Sponsor: University College, London
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Dec 25, 2013
P2, N=25, Recruiting, Sponsor: howard safran
- irinotecan / Generic mfg.
Enrollment closed, Metastases: Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Dec 25, 2013
P2, N=500, Active, not recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed, Metastases: APC-S1: Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers (clinicaltrials.gov) - Dec 25, 2013
P2, N=92, Active, not recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | New P2 trial: Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) - Dec 19, 2013
P2, N=138, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Orzel (UFT + Leucovorin) / EMD Serono, Otsuka
Trial withdrawal, Combination therapy, Metastases: Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors (clinicaltrials.gov) - Dec 17, 2013
P1, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Completed --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: FLOX + Cetuximab (Erbitux (clinicaltrials.gov) - Dec 17, 2013
P2, N=152, Completed, Sponsor: Odense University Hospital
Completed --> Withdrawn N=86 --> 152
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
New P4 trial: CCRe-IV: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (clinicaltrials.gov) - Dec 17, 2013
P4, N=336, Recruiting, Sponsor: Hospital Universitari de Bellvitge
- leucovorin calcium / Generic mfg.
New P1 trial, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Dec 17, 2013
P1, N=39, Not yet recruiting, Sponsor: City of Hope Medical Center
- | Trial completion, Metastases: New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma (clinicaltrials.gov) - Dec 17, 2013
P3, N=216, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
N=86 --> 152 Recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 17, 2013
P2/3, N=3240, Completed, Sponsor: Medical Research Council
Recruiting --> Completed Recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia (clinicaltrials.gov) - Dec 17, 2013
P2, N=120, Completed, Sponsor: Medical Research Council
Recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: DERMATUX: FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema (clinicaltrials.gov) - Dec 16, 2013
P4, N=165, Active, not recruiting, Sponsor: Dr. Carl Schimanski
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer (clinicaltrials.gov) - Dec 16, 2013
P3, N=1030, Completed, Sponsor: Royal Liverpool University Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 16, 2013
P3, N=0, Completed, Sponsor: Medical Research Council
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| conatumumab (AMG 655) / Amgen
Trial completion, Combination therapy, Metastases: Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 15, 2013
P1/2, N=202, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed